摘要
为实现到2050年在全球范围内根除结核病(Tuberculosis,TB)这一宏伟目标,迫切需要开发新的TB疫苗和疫苗接种策略。虽然卡介苗(Bacille Calmette-Guérin,BCG)在保护儿童免受粟粒性结核和结核性脑膜炎等方面获得了成功,但其对成人肺结核(Pulmonary tuberculosis,PTB)的保护效果仍然存在较大差异(0~80%)。目前,有包括第一代疫苗和第二代疫苗在内的几十种新型TB疫苗已处于临床前或临床研究的不同阶段,而作为第三代疫苗的核酸疫苗随着医药技术的发展也逐渐走入人们的视野。本文主要综述了TB DNA疫苗的免疫学机制、研究现状、免疫增强策略和TB DNA疫苗存在的问题与应用前景,以期为开发更安全、更高效的新型TB DNA疫苗提供新的思路和视角。
In order to achieve the grand goal of eliminating tuberculosis(TB)globally by 2050,it is urgently needed to develop novel TB vaccines and vaccination strategies.Although Bacille Calmette-Guérin(BCG)has been succeeded in protecting children from miliary tuberculosis and tuberculous meningitis,its protective effect on adult pulmonary tuberculosis(PTB)is still weak(0-80%).To date,a dozens of novel TB vaccines,including first-generation and second-generation vaccines,are in different stages of preclinical or clinical research.As the third-generation vaccine,nucleic acid vaccines have gradually entered people’s field of vision with the development of medical technology.This review mainly summarizes the immunological mechanism of TB DNA vaccine,the current status of TB DNA vaccine research,the strategy of TB DNA vaccine immunity enhancement,and the problems and application prospects of TB DNA vaccine.We hope to provide new ideas and perspectives for the development of safer and more efficient novel TB DNA vaccines.
作者
李军丽
赵爱华
LI Jun-li;ZHAO Ai-hua(Division of Tuberculosis Vaccine and Allergen,Institute of Biological Product Control,National Institutes for Food and Drug Control,Beijing 102629,China)
出处
《中国人兽共患病学报》
CAS
CSCD
北大核心
2022年第3期226-235,共10页
Chinese Journal of Zoonoses
基金
2020年北京市自然科学基金-海淀原始创新联合基金项目(No.L202040)。
关键词
结核分枝杆菌
结核病
BCG
核酸疫苗
DNA疫苗
Mycobacterium tuberculosis
tuberculosis
Bacille Calmette-Guérin
nucleic acid vaccine
DNA vaccine
